{"entity":{"id":"elias-jabbour","kind":"person","name":"Elias Jabbour","aka":[],"tldr":"Leukaemia specialist who built chemotherapy-light regimens combining inotuzumab, blinatumomab and ponatinib for adult ALL.","summary":"Elias Jabbour led the MD Anderson regimens combining low-intensity chemotherapy with inotuzumab ozogamicin and blinatumomab in older adults with ALL, and the chemotherapy-free ponatinib plus blinatumomab regimen for Philadelphia-positive ALL, which produce complete molecular remissions in most patients and challenge the need for transplant. He was senior author of INO-VATE and leads adult ALL research at MD Anderson.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jabbour%20E%5BAuthor%5D%20acute%20lymphoblastic%20leukemia%20blinatumomab"}],"tags":["all","immunotherapy","chemo-free"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":["t-cell-engager","adc"],"targets":["cd19","cd3"],"drugs":["blinatumomab"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["ino-vate"],"people":[],"bottlenecks":[],"keyPapers":["paper-ino-vate-inotuzumab-all-nejm-2016"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Leukemia, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Adult acute lymphoblastic leukaemia","Antibody and bispecific therapy","Chemotherapy-free regimens","Philadelphia-positive ALL"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jabbour%20E%5BAuthor%5D%20acute%20lymphoblastic%20leukemia%20blinatumomab"}],"papers":[{"title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","journal":"Lancet Haematology","year":2023,"doi":"10.1016/S2352-3026(22)00319-2"},{"title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia (INO-VATE)","journal":"NEJM","year":2016,"doi":"10.1056/NEJMoa1509277"}],"orcid":"0000-0003-4465-6119"},"route":"/people/elias-jabbour/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"drug":[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}],"trial":[{"id":"ino-vate","kind":"trial","name":"INO-VATE ALL","route":"/trials/ino-vate/"}],"paper":[{"id":"paper-ino-vate-inotuzumab-all-nejm-2016","kind":"paper","name":"INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL","route":"/key-papers/paper-ino-vate-inotuzumab-all-nejm-2016/"}]}}